Cargando…

Progesterone for the Prevention of Preterm Birth – an Update of Evidence-Based Indications

The prevention and treatment of preterm birth remains one of the biggest challenges in obstetrics. Worldwide, 11% of all children are born prematurely with far-reaching consequences for the children concerned, their families and the health system. Experimental studies suggest that progesterone inhib...

Descripción completa

Detalles Bibliográficos
Autores principales: Kuon, Ruben-J., Voß, Pauline, Rath, Werner
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Georg Thieme Verlag KG 2019
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6690740/
https://www.ncbi.nlm.nih.gov/pubmed/31423019
http://dx.doi.org/10.1055/a-0854-6472
_version_ 1783443236946182144
author Kuon, Ruben-J.
Voß, Pauline
Rath, Werner
author_facet Kuon, Ruben-J.
Voß, Pauline
Rath, Werner
author_sort Kuon, Ruben-J.
collection PubMed
description The prevention and treatment of preterm birth remains one of the biggest challenges in obstetrics. Worldwide, 11% of all children are born prematurely with far-reaching consequences for the children concerned, their families and the health system. Experimental studies suggest that progesterone inhibits uterine contractions, stabilises the cervix and has immunomodulatory effects. Recent years have seen the publication of numerous clinical trials using progestogens for the prevention of preterm birth. As a result of different inclusion criteria and the use of different progestogens and their methods of administration, it is difficult to draw comparisons between these studies. A critical evaluation of the available studies was therefore carried out on the basis of a search of the literature (1956 to 09/2018). Taking into account the most recent randomised, controlled studies, the following evidence-based recommendations emerge: In asymptomatic women with singleton pregnancies and a short cervical length on ultrasound of ≤ 25 mm before 24 weeks of gestation (WG), daily administration of vaginal progesterone (200 mg capsule or 90 mg gel) up until 36 + 6 WG leads to a significant reduction in the preterm birth rate and an improvement in neonatal outcome. The latest data also suggest positive effects of treatment with progesterone in cases of twin pregnancies with a short cervical length on ultrasound of ≤ 25 mm before 24 WG. The study data for the administration of progesterone in women with singleton pregnancies with a previous preterm birth have become much more heterogeneous, however. It is not possible to make a general recommendation for this indication at present, and decisions must therefore be made on a case-by-case basis. Even if progesterone use is considered to be safe in terms of possible long-term consequences, exposure should be avoided where it is not indicated. Careful patient selection is crucial for the success of treatment.
format Online
Article
Text
id pubmed-6690740
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Georg Thieme Verlag KG
record_format MEDLINE/PubMed
spelling pubmed-66907402019-08-14 Progesterone for the Prevention of Preterm Birth – an Update of Evidence-Based Indications Kuon, Ruben-J. Voß, Pauline Rath, Werner Geburtshilfe Frauenheilkd The prevention and treatment of preterm birth remains one of the biggest challenges in obstetrics. Worldwide, 11% of all children are born prematurely with far-reaching consequences for the children concerned, their families and the health system. Experimental studies suggest that progesterone inhibits uterine contractions, stabilises the cervix and has immunomodulatory effects. Recent years have seen the publication of numerous clinical trials using progestogens for the prevention of preterm birth. As a result of different inclusion criteria and the use of different progestogens and their methods of administration, it is difficult to draw comparisons between these studies. A critical evaluation of the available studies was therefore carried out on the basis of a search of the literature (1956 to 09/2018). Taking into account the most recent randomised, controlled studies, the following evidence-based recommendations emerge: In asymptomatic women with singleton pregnancies and a short cervical length on ultrasound of ≤ 25 mm before 24 weeks of gestation (WG), daily administration of vaginal progesterone (200 mg capsule or 90 mg gel) up until 36 + 6 WG leads to a significant reduction in the preterm birth rate and an improvement in neonatal outcome. The latest data also suggest positive effects of treatment with progesterone in cases of twin pregnancies with a short cervical length on ultrasound of ≤ 25 mm before 24 WG. The study data for the administration of progesterone in women with singleton pregnancies with a previous preterm birth have become much more heterogeneous, however. It is not possible to make a general recommendation for this indication at present, and decisions must therefore be made on a case-by-case basis. Even if progesterone use is considered to be safe in terms of possible long-term consequences, exposure should be avoided where it is not indicated. Careful patient selection is crucial for the success of treatment. Georg Thieme Verlag KG 2019-08 2019-08-12 /pmc/articles/PMC6690740/ /pubmed/31423019 http://dx.doi.org/10.1055/a-0854-6472 Text en https://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License, which permits unrestricted reproduction and distribution, for non-commercial purposes only; and use and reproduction, but not distribution, of adapted material for non-commercial purposes only, provided the original work is properly cited.
spellingShingle Kuon, Ruben-J.
Voß, Pauline
Rath, Werner
Progesterone for the Prevention of Preterm Birth – an Update of Evidence-Based Indications
title Progesterone for the Prevention of Preterm Birth – an Update of Evidence-Based Indications
title_full Progesterone for the Prevention of Preterm Birth – an Update of Evidence-Based Indications
title_fullStr Progesterone for the Prevention of Preterm Birth – an Update of Evidence-Based Indications
title_full_unstemmed Progesterone for the Prevention of Preterm Birth – an Update of Evidence-Based Indications
title_short Progesterone for the Prevention of Preterm Birth – an Update of Evidence-Based Indications
title_sort progesterone for the prevention of preterm birth – an update of evidence-based indications
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6690740/
https://www.ncbi.nlm.nih.gov/pubmed/31423019
http://dx.doi.org/10.1055/a-0854-6472
work_keys_str_mv AT kuonrubenj progesteroneforthepreventionofpretermbirthanupdateofevidencebasedindications
AT voßpauline progesteroneforthepreventionofpretermbirthanupdateofevidencebasedindications
AT rathwerner progesteroneforthepreventionofpretermbirthanupdateofevidencebasedindications